Teva Pharmaceutical Industries (NASDAQ: TEVA) reported Q3 EPS of $1.25, $0.02 better than the analyst estimate of $1.23. Revenue for the quarter came in at $4.34 billion versus the consensus estimate of $4.54 billion.

Earnings